Compare RRBI & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RRBI | RAPT |
|---|---|---|
| Founded | 1998 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 484.1M | 498.4M |
| IPO Year | 2019 | 2019 |
| Metric | RRBI | RAPT |
|---|---|---|
| Price | $75.75 | $35.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $67.00 | $57.00 |
| AVG Volume (30 Days) | 35.7K | ★ 365.9K |
| Earning Date | 01-30-2026 | 03-05-2026 |
| Dividend Yield | ★ 0.80% | N/A |
| EPS Growth | ★ 26.56 | N/A |
| EPS | ★ 6.01 | N/A |
| Revenue | ★ $119,363,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.57 | N/A |
| P/E Ratio | $12.48 | ★ N/A |
| Revenue Growth | ★ 12.57 | N/A |
| 52 Week Low | $46.33 | $5.67 |
| 52 Week High | $78.01 | $42.39 |
| Indicator | RRBI | RAPT |
|---|---|---|
| Relative Strength Index (RSI) | 63.02 | 55.37 |
| Support Level | $71.23 | $33.01 |
| Resistance Level | $73.81 | $35.42 |
| Average True Range (ATR) | 2.02 | 2.17 |
| MACD | 0.17 | 0.03 |
| Stochastic Oscillator | 96.90 | 83.95 |
Red River Bancshares Inc is the bank holding company for the red river bank. The principal business of the Bank is lending and accepting deposits from businesses, professionals, individuals, and public entities. The bank's primary deposit products are demand deposits, savings deposits, and time deposits. The bank maintains a diversified loan portfolio with a focus on commercial real estate (Owner Occupied and Non-Owner Occupied), one-to-four-family residential, commercial, and industrial loans, construction and development Loans, and others. also, provides Treasury Management Services, Private Banking Services, Brokerage Services, and Other Banking Services.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.